Myxoid LiposarcomaSymptoms, Doctors, Treatments, Advances & More
Myxoid Liposarcoma Overview
Learn About Myxoid Liposarcoma
- Myxoid liposarcoma
- MRCLS
- Myxoid/round cell liposarcoma
- Myxoliposarcoma
Rockefeller Outpatient Pavilion
Sandra D'angelo is an Oncologist practicing medicine in New York, New York. Dr. D'angelo is rated as an Elite provider by MediFind in the treatment of Myxoid Liposarcoma. She is also highly rated in 33 other conditions, according to our data. Her clinical expertise encompasses Synovial Sarcoma, Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, and Liver Embolization. Dr. D'angelo is currently accepting new patients.
Rogel Cancer Center
Scott Schuetze is an Oncologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Schuetze is rated as an Elite provider by MediFind in the treatment of Myxoid Liposarcoma. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Liposarcoma, Adult Soft Tissue Sarcoma, Angiosarcoma, and Myxoid Liposarcoma.
City Of Hope Comprehensive Cancer Center-Duarte
Lee Cranmer is an Oncologist practicing medicine in Duarte, California. Dr. Cranmer is rated as an Elite provider by MediFind in the treatment of Myxoid Liposarcoma. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, and Myxoid Liposarcoma.
Summary: This early phase I trial tests the safety and how well N-803 works in treating patients with synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCL) that is growing, spreading, or getting worse (progressive) after being treated with adoptive cellular therapy (ACT) using T-cell receptor therapy (T-CRT). Synovial sarcoma is a rare, slow-growing cancer that affects the soft tissues, like muscle...
Summary: The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma. This study will test different doses of mirdametinib in combination with a fixed dose of palbociclib to find the best safe dose for further testing.
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center
